Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

Kristian Reich; Frank O. Nestlé; Kim Papp; Jean‐Paul Ortonne; Robert J. Evans; Cynthia Guzzo; Shu Li; Lisa T. Dooley; Christopher Em Griffiths

doi:10.1016/s0140-6736(05)67566-6

Related publications

Article2006

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial

Kristian Reich, Frank O. Nestlé, Kim Papp, J.‐P. Ortonne, Yifang Wu, M Bala, Robert J. Evans, Cynthia Guzzo, Shuangyue Li, Lisa T. Dooley, Christopher Em Griffiths

Article2005

Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial

Alice B. Gottlieb, Christopher Em Griffiths, Vincent Ho, M. Lahfa, Ulrich Mrowietz, Dédée F. Murrell, Ortonne Jp, Gail Todd, Robert Cherill, I. N. Marks, Shahram Emady‐Azar, C. Paul

Article2008

Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.

Kristian Reich, Frank O. Nestlé, Ying Wu, Mohan Bala, D. Eisenberg, Cynthia Guzzo, Shu Li, Lisa T. Dooley, Christopher Em Griffiths

Article2010

Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial

Kristian Reich, Jean-Paul Ortonne, Urs Kerkmann, Yanxin Wang, J.‐H. Saurat, Kim Papp, Richard G. Langley, Christopher Em Griffiths

Article2015

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: A phase 3 randomized trial

Robert Bissonnette, Lars Iversen, Howard Sofen, Christopher Em Griffiths, Peter Foley, Ricardo Romiti, Mary Bachinsky, Scott T. Rottinghaus, Hsiewe Ying Tan, James Proulx, H. Valdez, Pankaj Gupta, Lotus Mallbris, Robert Wołk